Skip to content

LIFE SCIENCES DEVELOPMENT CAMPUS

Active
KBO/BCE: BE 0897.657.596
Watch Print / PDF
Full dossier in preparation

Checked processes every Belgian company, act by act, from the Belgian Official Gazette. The data below is real and verified, this company's full, act-by-act verified dossier is still being assembled.

Process with priority Sign in free to move this company to the front.
Age18 yrs
Board2
Staff (FTE)2.4
Connections21
Real estate1 parcel · 2.5 ha

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of LIFE SCIENCES DEVELOPMENT CAMPUS is 0.1% (very low). The 2025 annual accounts show equity of €9.18M and a net result of €317k. Equity is growing by ~4.9% per year across the filed fiscal years. Its solvency ranks better than 79% of 205 sector peers (fiscal year 2025). The company has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 8 annual accounts.

Signals

2 signals · with evidence
Strong solvency vs sector
Solvency is in the sector's strongest quartile: better than 79% of 205 peers (2025). A comfortable equity buffer.
View the sector comparison
Consistently profitable
Positive net result in the two most recent financial years (2024 and 2025).
View the result trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Trust signals

2 signals
Established
Founded in 2008, 18 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No administrative flags

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.1% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector −Annual accounts: healthy financial profile −Long track record −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

Turnover€1.78M+13.1%
EBIT margin12.9%+7.6pp
Net result€317k+169.4%
Working capital€-83k+82.2%

Annual accounts & ratios

Source: NBB · 2025
Annual accounts filed on 22-05-2026 with the NBB · fiscal year 2025 · volledig
€-1.00M€0€1.00M€2.00MRevenue 2021: €983k€983kOperating result 2021: €-290k€-290kNet result 2021: €-253k€-253kRevenue 2022: €1.13M€1.13MOperating result 2022: €-421k€-421kNet result 2022: €-383k€-383kRevenue 2023: €1.29M€1.29MOperating result 2023: €-67k€-67kNet result 2023: €-93k€-93kRevenue 2024: €1.57M€1.57MOperating result 2024: €83k€83kNet result 2024: €118k€118kRevenue 2025: €1.78M€1.78MOperating result 2025: €230k€230kNet result 2025: €317k€317k20212022202320242025
RevenueOperating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~4.9%/year over 8 fiscal years, indicative, assuming unchanged policy.
€2.50M€5.00M€7.50M€10.00M€12.50M2026: €9.89M (€8.62M - €11.16M)2027: €10.38M (€8.35M - €12.41M)2028: €10.89M (€8.10M - €13.68M)2018: €5.08M2019: €4.86M2020: €8.94M2021: €8.63M2022: €8.11M2023: €9.12M2024: €9.05M2025: €9.18M20182019202020212022202320242025202620272028
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2025 · NACE 68, Real estate activities · compared within the same schema type (full schema)
Metric This company Sector median Position in the sector
Solvency 75.6% 31.0%
better than 79% of 205 sector peers
Net result €317k €9k
better than 85% of 204 sector peers
Equity €9.18M €503k
better than 82% of 205 sector peers
Staff costs €236k €184k
higher than 60% of 39 sector peers
Employees (FTE) 2.4 1.3
better than 63% of 49 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P79
2020: P77 · n=2712021: P78 · n=3532022: P78 · n=5472023: P80 · n=6562024: P82 · n=7762025: P79 · n=2052020 2025
Stable position over 2020-2025 · n=205-776
Net result P85
2020: P17 · n=2702021: P10 · n=3522022: P8 · n=5452023: P19 · n=6522024: P83 · n=7742025: P85 · n=2042020 2025
Improving position over 2020-2025 · n=204-774
Equity P82
2020: P85 · n=2722021: P86 · n=3532022: P89 · n=5472023: P90 · n=6562024: P91 · n=7762025: P82 · n=2052020 2025
Stable position over 2020-2025 · n=205-776
Staff costs P60
2021: P67 · n=1022022: P62 · n=1262023: P64 · n=1302024: P70 · n=1332025: P60 · n=392021 2025
Stable position over 2021-2025 · n=39-133
Describes the position versus peers, not a forecast.
Revenue
€1.78M
+13.1% 18-25
EBITDA
€861k
+19.6% 18-25
Net profit
€317k
+169.4% 18-25
Cash flow
€948k
+25.7% 18-25
Total assets
€12.14M
-3.2% 18-25
Equity
€9.18M
+1.4% 18-25
Working capital
€-83k
+82.2% 18-25
Employees (FTE)
2
0.0% 18-25
Staff costs
€236k
+7.1% 18-25
Income taxes
€380
+5.6% 18-25
Debt
€2.97M
-15.0% 18-25
Debt ≤ 1y
€790k
-17.9% 18-25
Debt > 1y
€2.17M
-13.6% 18-25
Current ratio
0.90
+73.8% 18-25
Quick ratio
0.90
+73.8% 18-25
Solvency
75.6%
+4.7% 18-25
Debt / equity
0.32
-16.2% 18-25
ROE
3.5%
+165.7% 18-25
ROA
2.6%
+178.2% 18-25
Net margin
17.8%
+138.2% 18-25
EBITDA margin
48.4%
+5.7% 18-25
Interest coverage
8.37
+80.8% 18-25
Figures by fiscal year
Fiscal year2025
Revenue€1.78M
EBITDA€861k
Net profit€317k
Cash flow€948k
Staff costs€236k
Income taxes€380
Dividends-
Total assets€12.14M
Equity€9.18M
Debt€2.97M
of which ≤ 1y€790k
of which > 1y€2.17M
Working capital€-83k
Employees (FTE)2.4
Ratios (computed)
2025
Current ratio0.90
Quick ratio0.90
Working capital ratio-0.7%
Solvency75.6%
Debt / equity0.32
Long-term debt ratio0.24
Interest coverage8.37
Gross margin-
Net margin17.8%
ROA2.6%
ROE3.5%
EBITDA margin48.4%
Days sales outstanding57d
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€12.14M
Fixed assets 21/28€11.44M
Intangible fixed assets 21€0
Tangible fixed assets 22/27€11.44M
Financial fixed assets 28€122
Current assets 29/58€708k
Amounts receivable within one year 40/41€282k
Cash & bank 54/58€402k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€12.14M
Equity 10/15€9.18M
Contributions / capital 10/11€9.22M
Accumulated profits (losses) 14€-3.67M
Amounts payable 17/49€2.97M
Amounts payable after one year 17€2.17M
Amounts payable within one year 42/48€790k
Trade debts payable within one year 44€119k
Income statement
Turnover 70€1.78M
Operating result 9901€230k
Financial income 75€191k
Financial charges 65€103k
Result before taxes 9903€317k
Income taxes 67/77€380
Net result for the period 9904€317k
Result to be appropriated 9905€317k
You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2025 · computed
77 / 100 Excellent
050100

Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.

See plans →
Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative, not credit advice.

Directors

Directors & mandates

9 directors
Current directors & mandates
  • Somers, Veerle
    Director
    State Gazette act 22098808 (17-08-2022)
    Current
    24-06-2022 → present
  • De Winter, Leny
    Director
    State Gazette act 22098808 (17-08-2022)
    Current
    29-04-2022 → present
Historic, not recently confirmed (4)
These mandates remain open in the register but have not been confirmed by a new act in over six years. They do not count as active directors.
  • Piet Stinissen
    Director
    State Gazette act 20085015 (24-07-2020)
    Not recently confirmed
    last confirmed in an act from 2020
  • Tom Vandeput
    Director
    State Gazette act 20085015 (24-07-2020)
    Not recently confirmed
    last confirmed in an act from 2020
    2 events
    • 24-04-2020 Appointed· Director
    • 21-02-2019 Appointed· Director
  • Pieter Stinissen
    Director
    State Gazette act 15098289 (09-07-2015)
    Not recently confirmed
    last confirmed in an act from 2015
  • BVBA Life Sciences ConsultingLegal entity
    Director· perm. rep.: Kris Motmans
    State Gazette act 11039788 (14-03-2011)
    Not recently confirmed
    last confirmed in an act from 2011
Former directors (3)
  • Frank Smeets
    Director
    State Gazette act 19043664 (29-03-2019)
    Former
    06-09-2018 → 01-01-2019
    2 events
    • 01-01-2019 Resigned· Director
    • 06-09-2018 Appointed· Director
  • Erik Gerits
    Director
    State Gazette act 16120756 (29-08-2016)
    Former
    12-04-2016 → 29-06-2018
    2 events
    • 29-06-2018 Resigned· Director
    • 12-04-2016 Appointed· Director
  • Marc Vandeput
    Director
    State Gazette act 15098289 (09-07-2015)
    Former
    25-04-2014 → 29-08-2016
    2 events
    • 29-08-2016 Resigned· Director
    • 25-04-2014 Mandate renewed· Director
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.

Statutory auditor

1 auditor
Statutory auditor IRE/IBR number Tenure
Ernst et Young Reviseurs d'EntreprisesCurrent
Statutory auditor · represented by Stefan Olivier
 - 30-04-2021 → present
Appointed statutory auditor from the Belgian State Gazette. The IRE/IBR number refers to the register of the Institute of Registered Auditors.

Insolvency mandates

No insolvency mandates (liquidators, administrators) on record for this company.

Legal Structure

NACE primary Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen(68203)
Legal form Public limited company(014)
Incorporation25-04-2008
StatusActive
Postal code3590

Structure & network

Connections & network

21 connected companies
Ernst et Young Reviseurs d'Entreprises, Parent company EEErnst et YoungReviseur…rises+20 companies via a shared address +20via a sharedaddressLIFE SCIENCES DEVELOPMENT CAMPUS LIFESCIENCE…MPUS0897.657.596
Group structureShared address / shareholderBundled connections
Group structure
Ernst et Young Reviseurs d'Entreprises
Parent · 926 subsidiaries · 5 locations
Control→
Network connections
be-MINE
Shared address
→
BERIGIS
Shared address
→
CERIGIS
Shared address
→
CORDA CAMPUS 2.0
Shared address
→
DERIGIS
Shared address
→
Ed. Proj. Epsilon
Shared address
→
Ed. Proj. Gamma
Shared address
→
Ed. Proj. Phi
Shared address
→
H.W.P.
Shared address
→
HOUTPARK
Shared address
→
Kristalpark III
Shared address
→
LRM Beheer
Shared address
→
MIJNEN
Shared address
→
QOMPIUM
Shared address
→
RE-SOLE
Shared address
→
SolarPulse VII
Shared address
→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.

Locations & real estate

Registered office

on the map · from the address register
seat.Municipality approximate (street level)

Establishment units

1 location
LIFE SCIENCES DEVELOPMENT CAMPUS NV
Agoralaan A-bis, 3590 DiepenbeekProjectontwikkeling voor kantoorbouw
since 20082.172.738.137
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area2.5 ha

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
71011A0272/00F000 Flanders 2.5 ha - -
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgisch Staatsblad · acts

18 acts
Capital history · 3
22-09-2023
v3.2
30-09-2020
v3.2
09-02-2015
v3.2
Address history · 1
04-07-2017
v3.2
All acts · 18 updated 3 months ago
2026
08-05-2026 General meeting · Officer resignation · Officer appointment · Permanent representative Open-capture extraction
  • Filing: 2026-04-07 · Life Sciences Development Campus
  • Publication: 2026-05-08 · Life Sciences Development Campus
  • General meeting: 2025-09-15 · Life Sciences Development Campus
  • Officer resignation: 2025-06-23 · Tom Vandeput
  • Officer appointment: end: 2026, role: bestuurder, start: 2025-06-23 · POM Limburg
  • Permanent representative · Roeland Buckinx
  • Act object: Ontslag en benoeming bestuurder
Summary: General meeting · Officer resignation · Officer appointment · Permanent representative
2024
03-06-2024 EY Bedrijfsrevisoren reappointed as statutory auditor Director changes
  • EY Bedrijfsrevisoren, Commissaris
Summary: v3.2
08-01-2024 Publication in the Belgian Official Gazette, Minor change Minor change·Marc JANSEN
Summary: Agm reschedulingNotary: Marc JANSEN · HasseltFirm: MARC JANSEN & ARVID LEROI, geassocieerde notarissen
2023
22-09-2023 Capital increase of €486,667 to €8,473,667 Capital & shares
  • €7.987.000 → €8.473.667
Summary: v3.2
24-08-2023 Gert Vandewaerde reappointed as director Director changes
  • Gert Vandewaerde, Bestuurder
Summary: v3.2
2022
17-08-2022 2 directors appointed Director changes
  • De Winter, Leny, Bestuurder
  • Somers, Veerle, Bestuurder
Summary: v3.2
2021
24-09-2021 Stefan Olivier appointed as statutory auditor Director changes
  • Stefan Olivier, Commissaris
Summary: v3.2
2020
30-09-2020 Capital increase of €1,500,000 to €6,937,000 Capital & shares
  • €5.437.000 → €6.937.000
  • 2 kapitaalbewegingen in deze akte
Summary: v3.2
24-07-2020 4 directors appointed Director changes
  • Tom Vanham, Bestuurder
  • Theo Donné, Bestuurder
  • Tom Vandeput, Bestuurder
  • Piet Stinissen, Bestuurder
Summary: v3.2
2019
09-04-2019 Klynveld, Peat Marwick Goerdeler Bedrijfsrevisoren reappointed as statutory auditor Director changes
  • Klynveld, Peat Marwick Goerdeler Bedrijfsrevisoren, Commissaris
Summary: v3.2
29-03-2019 2 directors appointed, 2 resigning Director changes
  • Frank Smeets, Bestuurder
  • Tom Vandeput, Bestuurder
  • Erik Gerits, Bestuurder
  • Frank Smeets, Bestuurder
Summary: v3.2
2018
17-01-2018 Change in the board of directors Director changes
Summary: v3.2
2017
04-07-2017 Registered office moved from Hasselt to Diepenbeek Registered-office change
  • Kempische Steenweg 311, 3500 Hasselt → Agoralaan A-bis, 3590 Diepenbeek
Summary: v3.2
2016
29-08-2016 1 director appointed, 1 resigning Director changes
  • Gerits Erik, Bestuurder
  • Marc Vandeput, Bestuurder
Summary: v3.2
2015
16-12-2015 Change in the board of directors Director changes
Summary: v3.2
09-07-2015 1 director appointed, 4 reappointed Director changes
  • LRM NV, Bestuurder
  • Marc Vandeput, Bestuurder
  • Pieter Stinissen, Bestuurder
  • LRM Beheer NV, Bestuurder
  • KPMG Bedrijfsrevisoren, Commissaris
Summary: v3.2
09-02-2015 Capital increase of €5,000 to €5,437,000 Capital & shares
  • €5.432.000 → €5.437.000
Summary: v3.2
2011
14-03-2011 Kris Motmans appointed as director Director changes
  • Kris Motmans, Bestuurder
Summary: v3.2

Analysis

Snowflake analysis

financial profile on 5 axes
Health77Profitability72Solvency75Growth76Stability100
80 / 100

Exceptional profile, strong across almost every axis.

Health 77
Profitability 72
Solvency 75
Growth 76
Stability 100

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Same sector, ranked by comparable size

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Verhuur en exploitatie van eigen of geleasd niet-residentieel onroerend goed, exclusief terreinen68203Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen68203Overige zakelijke dienstverlening, n.e.g.82990Overige zakelijke dienstverlening, neg82990
Primary activity highlighted.
Names & trade names
Legal nameNL LIFE SCIENCES DEVELOPMENT CAMPUS
AbbreviationNL LSDC
Registered office
Agoralaan A-bis
3590 Diepenbeek, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.